PO
POSC.US Positron Corp
- Market cap
- USD 54.2M
- P/E
- -
- P/B
- 370.36x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is POSC.US undervalued?
Graham numberThe Graham number of Positron Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Positron Corp fundamental analysis
No fundamental analysis for Positron Corp yet.
Positron Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Positron Corp
Positron Corporation, a medical technology company, co-develops, manufactures, and sells positron emission tomography and PET-computed tomography imaging systems in the United States. The company offers Attrius PET and NeuSight PET-CT 64-slice used in non-invasive diagnosis and evaluation of coronary artery disease and supports various molecular imaging applications, including cardiology, oncology, and neurology. It also provides clinical and technical support services, such…
Full company profilePositron Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Positron Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.63M | 1.47M | 1.45M | 778K | 824K | 882K | 728K | 735K | 588K | 461K | 434K |
| Gross Profit | 424K | 104K | 63.8K | 185K | 161K | 133K | -81.8K | -353K | -342K | -2.11M | -1.57M |
| Operating Income | -3.34M | -2.74M | 12.6K | -20.8K | -62.1K | -764K | -2.68M | -1.36M | -2.21M | -10.5M | -4.12M |
| EBITDA | -4.81M | -609K | 22.1K | -656.00 | -38.5K | -568K | -2.77M | -1.45M | -2.18M | -10.4M | -4.04M |
| Net Income | -7.10M | -2.58M | 12.6K | -20.8K | -62.1K | -595K | -2.86M | -1.64M | -2.39M | -10.6M | -4.23M |
| EPS | -1.96 | -0.28 | 0.00 | 0.00 | -0.01 | -0.03 | -0.12 | -0.07 | -0.09 | -0.34 | -0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 3.88M | 1.87M | 502K | 424K | 451K | 1.96M | 1.77M | 1.77M | 1.80M | 4.00M | 3.66M |
| Total Liabilities | 15.1M | 2.71M | 1.21M | 1.15M | 510K | 342K | 1.89M | 2.03M | 2.21M | 2.56M | 4.21M |
| Shareholders' Equity | -11.2M | -837K | -708K | -729K | -59.0K | 1.62M | -121K | -258K | -413K | 1.44M | -550K |
| Cash & Short-term Investments | 1.74M | 208K | 64.9K | 26.1K | 28.2K | 1.41M | 71.3K | 101K | 69.8K | 2.52M | 1.93M |
| Total Debt | 5.02M | 470K | 1.12M | 1.10M | 463K | 318K | 1.54M | 1.79M | 1.80M | 1.95M | 3.09M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.05M | -2.42M | 95.6K | -2.57K | -105K | -616K | -2.54M | -1.60M | -1.73M | -4.70M | -3.23M |
| Capital Expenditure | 16.0K | 26.0K | 0.00 | 35.8K | 5.00 | 93.0K | 0.00 | 3.00 | 2.00 | 99.0K | 0.00 |
| Free Cash Flow | -3.06M | -2.44M | 95.6K | -38.4K | -105K | -709K | -2.54M | -1.60M | -1.73M | -4.80M | -3.23M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -36.7% | - | - | - | -734.4% | - |
| ROA | -183.0% | -138.3% | 2.5% | -4.9% | -13.7% | -30.3% | -161.8% | -92.7% | -132.6% | -265.1% | -115.6% |
| Net Profit Margin | -435.8% | -176.3% | 0.9% | -2.7% | -7.5% | -67.5% | -392.9% | -223.1% | -406.5% | -2,297.8% | -974.3% |
| Debt to Equity | - | - | - | - | - | 0.20x | - | - | - | 1.35x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Positron Corp dividends
Positron Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:400 on Apr 8, 2015.
Who owns Positron Corp
- Insiders 54.23%
- Institutions 0.00%
- Public & others 45.77%
- Shares outstanding 32.8M
- Free float 15.0M
Positron Corp company profile
- Company name
- Positron Corp
- Ticker
- POSC.US
- Exchange
- USA Stocks
- Listed since
- Dec 3, 1993
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 10
- Fiscal year end
- December
- Address
- 3784 Commerce Court, North Tonawanda, NY, United States, 14120
- Phone
- 727 287 2800
- Website
- positron.com
About Positron Corp
Positron Corporation, a medical technology company, co-develops, manufactures, and sells positron emission tomography and PET-computed tomography imaging systems in the United States. The company offers Attrius PET and NeuSight PET-CT 64-slice used in non-invasive diagnosis and evaluation of coronary artery disease and supports various molecular imaging applications, including cardiology, oncology, and neurology. It also provides clinical and technical support services, such as physician interpretation training, nurse and technologist training, billing and prior-authorization assistance, physician over-read services, 24/7 clinical and technical support, priority response with after-hours service availability, equipment uptime guarantees and software upgrades, and remote system diagnostics and maintenance capabilities. The company sells its products through internal sales and marketing team. It serves healthcare providers, imaging centers, hospitals, and cardiology practices. The company was incorporated in 1983 and is headquartered in North Tonawanda, New York.
Positron Corp management
2- Mr. Adel AbdullahPresident & Chairman · born 1974
- Mr. Aaron HargraveVice President · born 1986